Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJHemOnc is pleased to be media partner for the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which was held on October 27-30 2022 in Berlin, Germany, and virtually. This meeting is an opportunity for experts to come together and debate key topics of discussion in the field of transplantation and cellular therapies in hematological malignancies. For more information about COSTEM, visit costemlive.cme-congresses.com
View all videos

COSTEM 2022

The 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies
27–30 October 2022 | Berlin, Germany / Online

COSTEM 2022

The 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies
27–30 October 2022 | Berlin, Germany / Online
VJHemOnc is pleased to be media partner for the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which was held on October 27-30 2022 in Berlin, Germany, and virtually. This meeting is an opportunity for experts to come together and debate key topics of discussion in the field of transplantation and cellular therapies in hematological malignancies. For more information about COSTEM, visit costemlive.cme-congresses.com
View all videos

Latest Videos

View all
1:59
The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence
Alberto Mussetti • 28 Oct 2022
6:27
Could allogeneic stem cell transplantation be avoided in patients with Ph+ ALL?
Robin Foà • 24 Oct 2022
1:51
Insights into the efficacy of different strategies to prevent acute & chronic GvHD
Christopher Kanakry • 28 Oct 2022
1:35
The role of CAR-T therapy in high-risk LBCL in the first and second-line settings
Alberto Mussetti • 28 Oct 2022

Transplantation

View all
6:27
Could allogeneic stem cell transplantation be avoided in patients with Ph+ ALL?
Robin Foà • 24 Oct 2022
1:51
Insights into the efficacy of different strategies to prevent acute & chronic GvHD
Christopher Kanakry • 28 Oct 2022

Cellular Therapy

View all
1:59
The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence
Alberto Mussetti • 28 Oct 2022
1:35
The role of CAR-T therapy in high-risk LBCL in the first and second-line settings
Alberto Mussetti • 28 Oct 2022

Lymphoma

View all
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
2:11
The role of MRD in patients with NHL
Robin Foà • 24 Oct 2022

Leukemia

View all
6:27
Could allogeneic stem cell transplantation be avoided in patients with Ph+ ALL?
Robin Foà • 24 Oct 2022
1:52
The evolving role of CAR-T therapy & transplantation in adult ALL
Arnon Nagler • 28 Oct 2022
The content of VJHemOnc is intended for healthcare professionals